Biologics are driving GI costs. But they’re not the real problem.
Inflammatory bowel disease (IBD) is one of the costliest, most complex conditions in many health plan populations, driven by diagnostic delays, fragmented care, and late stage escalation to high cost drugs.
Biologics can exceed $100K per member per year, and once started, many patients remain on therapy for years. Attempts to restrict access can backfire, leading to relapse, ED visits, and higher total cost of care.
The fix isn’t less care. It’s smarter care.
Plans need earlier detection, better triage, and integrated GI support that complements biologic therapy rather than reacting after costs escalate.
Inside the whitepaper, you’ll learn:
- Why biologics alone aren’t solving IBD and what’s missing.
- How delayed GI care inflates pharmacy and ED spend.
- What plans can do today to reduce cost without restricting access.
- Real-world results, including 25% drop in GI pharmacy spend.
This isn’t about denial or de-escalation
It’s about using clinical logic, data, and right fit care to manage one of the largest drivers of GI cost.
